The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis

NCT02632786 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

129

Enrollment

INDUSTRY

Sponsor class

Conditions

AL Amyloidosis

Interventions

DRUG: NEOD001
DRUG: Placebo

Sponsor

Prothena Biosciences Ltd.